Out-licensing

Messenger Biopharma will not develop its own mRNA products.

We are eager to out-license our Aegis biotechnology to pharmaceutical and biotech companies for vaccine and gene therapy products development.

Last news

business-model

Messenger Biopharma in the newspaper “La Montagne”

posted February 15, 2016

“Messenger Biopharma in the newspaper “La ...Read More